Abbonarsi

Utilizing natural language processing and large language models in the diagnosis and prediction of infectious diseases: A systematic review - 15/08/24

Doi : 10.1016/j.ajic.2024.03.016 
Mahmud Omar a, , Dana Brin b, Benjamin Glicksberg c, d, Eyal Klang d
a Tel-aviv university, Faculty of medicine, Tel-Aviv, Israel 
b Division of Diagnostic Imaging, Sheba Medical Center, Affiliated to Tel-Aviv University, Ramat Gan, Israel 
c Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY 
d The Division of Data-Driven and Digital Medicine (D3M), Icahn School of Medicine at Mount Sinai, New York, NY 

Address correspondence to Mahmud Omar, Tel-aviv university, Faculty of medicine, Tel-Aviv, Israel.Tel-aviv university, Faculty of medicineTel-AvivIsrael

Riassunto

Background

Natural Language Processing (NLP) and Large Language Models (LLMs) hold largely untapped potential in infectious disease management. This review explores their current use and uncovers areas needing more attention.

Methods

This analysis followed systematic review procedures, registered with the Prospective Register of Systematic Reviews. We conducted a search across major databases including PubMed, Embase, Web of Science, and Scopus, up to December 2023, using keywords related to NLP, LLM, and infectious diseases. We also employed the Quality Assessment of Diagnostic Accuracy Studies-2 tool for evaluating the quality and robustness of the included studies.

Results

Our review identified 15 studies with diverse applications of NLP in infectious disease management. Notable examples include GPT-4's application in detecting urinary tract infections and BERTweet's use in Lyme Disease surveillance through social media analysis. These models demonstrated effective disease monitoring and public health tracking capabilities. However, the effectiveness varied across studies. For instance, while some NLP tools showed high accuracy in pneumonia detection and high sensitivity in identifying invasive mold diseases from medical reports, others fell short in areas like bloodstream infection management.

Conclusions

This review highlights the yet-to-be-fully-realized promise of NLP and LLMs in infectious disease management. It calls for more exploration to fully harness AI's capabilities, particularly in the areas of diagnosis, surveillance, predicting disease courses, and tracking epidemiological trends.

Il testo completo di questo articolo è disponibile in PDF.

Highlights

AI, especially NLP and LLMs, could enhance infectious disease diagnosis and prediction.
NLP models excel in disease detection and public health surveillance.
Results from included studies show varied NLP effectiveness across diseases.
Challenges in AI and NLP applications include data bias and accuracy.
Further research is essential to maximize AI potential in healthcare and infectious diseases.

Il testo completo di questo articolo è disponibile in PDF.

Key Words : AI in public health surveillance, Infectious disease management


Mappa


 Conflicts of interest: None to report.


© 2024  Association for Professionals in Infection Control and Epidemiology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 52 - N° 9

P. 992-1001 - settembre 2024 Ritorno al numero
Articolo precedente Articolo precedente
  • Blood culture algorithm implementation in emergency department patients as a diagnostic stewardship intervention
  • Rebecca Theophanous, John Ramos, Alyssa R. Calland, Rachel Krcmar, Priya Shah, Lucas T. da Matta, Stephen Shaheen, Rebekah H. Wrenn, Jessica Seidelman
| Articolo seguente Articolo seguente
  • International Nosocomial Infection Control Consortium (INICC) report of health care associated infections, data summary of 45 countries for 2015 to 2020, adult and pediatric units, device-associated module
  • Victor D. Rosenthal, Ruijie Yin, Patricio Nercelles, Sara E. Rivera-Molina, Somani Jyoti, Reshma Dongol, Daisy Aguilar-De-Moros, Nellie Tumu, Johana Alarcon-Rua, Juan P. Stagnaro, Safaa Alkhawaja, Luisa F. Jimenez-Alvarez, Yuliana A. Cano-Medina, Sandra L. Valderrama-Beltran, Claudia M. Henao-Rodas, Maria A. Zuniga-Chavarria, Amani El-Kholy, Hala Mounir Agha, Suneeta Sahu, Siksha O. Anusandhan, Mahuya Bhattacharyya, Mohit Kharbanda, Aruna Poojary, Pravin K. Nair, Sheila N. Myatra, Rajesh Chawla, Kavita Sandhu, Yatin Mehta, Prasad Rajhans, Farid Zand, Mohammad Abdellatif-Daboor, Chian-Wern Tai, Chin S. Gan, Mohd-Basri Mat Nor, Guadalupe Aguirre-Avalos, Blanca E. Hernandez-Chena, Alejandro Sassoe-Gonzalez, Isabel Villegas-Mota, Mary C. Aleman- Bocanegra, Ider Bat-Erdene, Nilton Y. Carreazo, Alex Castaneda-Sabogal, Jarosław Janc, Vladislav Belskiy, Sona Hlinkova, Dincer Yildizdas, Merve Havan, Alper Koker, Hulya Sungurtekin, Ener C. Dinleyici, Ertugrul Guclu, Lili Tao, Ziad A. Memish, Zhilin Jin

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.